Onconetix, Inc. develops and commercializes biotechnology solutions for men's health and oncology, with Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union, as a core company-specific product. News about ONCO commonly centers on diagnostic commercialization, clinical or regulatory disclosures, operating and financial results, and material agreements tied to its biotechnology business.
Company updates also cover capital-structure actions, including preferred stock and warrant financings, shareholder votes, reverse stock splits, Nasdaq listing compliance matters, and board or executive governance changes.
Onconetix (Nasdaq: ONCO) announced board approval of a 1-for-10 reverse stock split, expected to take effect on November 6, 2026.
The expected effective time is 12:01 a.m. Eastern Time. Outstanding common shares will fall from approximately 5,886,774 as of October 21, 2026, to approximately 588,677, before fractional-share adjustments. Shareholders will receive cash instead of fractional shares. Ownership percentages will otherwise remain unchanged, as will common shareholders’ rights and privileges. Proportionate adjustments will apply, under their respective terms, to exercise or conversion prices and shares issuable under outstanding options, warrants, convertible securities and equity incentive plans.
Onconetix (ONCO) advanced another $500,000 to Realbotix LLC under a bridge financing facility supporting its pending acquisition of the company. Total principal outstanding is now $3,000,000 under the facility, which permits aggregate loans of up to $5,000,000.
The facility bears no interest before the Share Exchange Agreement closes. At closing, the note and all obligations under it will be automatically cancelled and discharged. Cash required at closing will be reduced by total principal advanced plus an additional $500,000. If the agreement is terminated, interest accrues at 12% per annum from termination.
Onconetix agreed to acquire 100% of Realbotix’s equity in an all-stock transaction. Closing remains subject to Onconetix shareholder approval, required regulatory approvals and other conditions. The combined company is expected to trade on Nasdaq after closing.
SRX Global (SRXH) added an investment in Onconetix (ONCO) and updated shareholders on the liquidation of two portfolio holdings.
The holdings are Vistagen Therapeutics (VTGN) and Greenland Mines (GRML). SRX said it added Onconetix in anticipation of the closing of Onconetix's previously announced agreement to acquire Realbotix. Realbotix developed Vinci, an AI vision system that places cameras and tracking lenses inside robotic eyes. The system is described as detecting motion, recognizing returning users and identifying objects or colors.
Onconetix (ONCO) has provided Realbotix LLC with a non-interest-bearing bridge financing facility of up to $5,000,000 while their pending acquisition progresses toward closing.
The facility allows an aggregate principal of up to $5,000,000, including an initial advance of $2,500,000 to support Realbotix's growth and working capital needs. The financing is tied to the Share Exchange Agreement announced on February 12, 2026, under which Onconetix plans to acquire 100% of Realbotix in an all-stock transaction. Upon closing, the note and all related obligations are automatically cancelled, and the cash required at closing is reduced by the total principal advanced plus an additional $500,000. If the Share Exchange Agreement is terminated, interest on the outstanding amount accrues at 12% per annum from the termination date. The combined company is expected to trade on Nasdaq after closing, which remains subject to shareholder and regulatory approvals and other conditions.
Onconetix (ONCO) has provided Realbotix LLC, its pending acquisition target, with a non-interest bearing bridge financing facility of up to $5 million as of September 14, 2026.
The facility carries an aggregate principal limit of $5,000,000, including an initial advance of $2,500,000, to fund Realbotix’s growth and working capital while the parties work toward closing their Share Exchange Agreement. The facility bears no interest before closing. At the acquisition closing, the note and all related obligations will be automatically cancelled and discharged in full, and the cash required at closing will be reduced by the total principal advanced plus an additional $500,000. If the Share Exchange Agreement is terminated instead of closing, interest on the outstanding principal will accrue at 12% per annum from the termination date. The acquisition remains an all-stock deal for 100% of Realbotix’s equity interests, with the combined company expected to trade on Nasdaq after closing, subject to shareholder and regulatory approvals and other conditions.
Onconetix (ONCO) reports that its acquisition target Realbotix LLC has launched a pilot program with a leading European telecommunications company to deploy humanoid robots in live presentations and events.
The pilot will test Realbotix robots as presenters, hosts, and brand ambassadors in real-world, audience-facing environments, including corporate events, live product demonstrations, customer engagement, training support, hospitality and retail assistance, public information services, reception and concierge roles, and guided visitor experiences. It will also evaluate how the Realbotix platform can be configured to a partner’s specific workflows.
On February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of the equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, anticipated in the second half of 2026, subject to shareholder and regulatory approvals and other closing conditions.
Realbotix Corp. (TSX-V: XBOT, OTC: XBOTF) reported Q3-2026 consolidated revenue of $354,000 and nine‑month revenue of $932,000, down from $595,000 and $2,138,000 a year earlier, mainly due to repositioning Intima LLC and winding down crypto-related operations while investing in Realbotix LLC.
Q3 gross margin fell to 24.4% (from 37.1%), and operating expenses rose to $1.821 million, reflecting hiring and manufacturing scale-up for humanoid robotics and AI. Total comprehensive loss was $(1.695) million for Q3 and $(2.544) million for nine months, versus $12,000 and $(3.928) million in the prior-year periods, with current-year results aided by one-time gains on debt repayment and sale of the Tokens.com domain.
Realbotix LLC, now generating revenue of $132,000 in Q3 versus nil last year, expanded its team to over 20 FTEs and plans a new Echo Generation One robot line. Realbotix has agreed to list Realbotix LLC on Nasdaq via an all-share reverse takeover of Onconetix (NASDAQ: ONCO), expected to close in Q4-2026, with Realbotix retaining majority ownership of ONCO common shares.
Onconetix (Nasdaq: ONCO) reported that its pending acquisition target Realbotix LLC has entered an agreement with a recognized streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-awarded television series.
According to Onconetix, this entertainment agreement adds to Realbotix’s existing deployments in education, healthcare, hospitality and customer engagement. On February 12, 2026, Onconetix signed a definitive all-stock share exchange to acquire 100% of Realbotix LLC. The combined company is expected to trade on Nasdaq after closing, anticipated in the second half of 2026, subject to shareholder and regulatory approvals and other conditions.
Onconetix (Nasdaq: ONCO) announced that its wholly owned Swiss subsidiary, Proteomedix AG, has appointed co-founder Ralph Schiess, PhD to the Proteomedix Board of Directors. The appointment was approved at the Proteomedix Annual General Meeting of Shareholders held on June 22, 2026, where Thomas Meier, PhD was also re-elected for an additional one-year term as Chairman.
According to Onconetix, Dr. Schiess co-developed Proclarix, the CE-IVD certified prostate cancer diagnostic blood test originating from ETH Zürich, and previously served as Proteomedix CEO, leading biomarker discovery efforts that resulted in Proclarix. Proteomedix was acquired by Onconetix in December 2023. Dr. Schiess also serves as founding CEO of ZH3D at the University of Zürich and holds advanced degrees from the University of Zürich and ETH Zürich.
Realbotix Corp outlines its holding company structure, highlighting two independently operated subsidiaries: Realbotix LLC, focused on AI-powered humanoid robotics for commercial and enterprise applications, and Intima LLC, an online direct-to-consumer adult wellness and companionship business that owns 86% of RealDoll. Realbotix LLC has its own facility, leadership led by Andrew Kiguel, and about 25 employees dedicated to non-adult robotics and embodied AI, with no shared staff, products, or technology with Intima or RealDoll. A previously announced proposed all-stock merger between Realbotix LLC and Onconetix (NASDAQ: ONCO) is expected, subject to approvals, to close in the second half of 2026. Realbotix has also retained legal counsel to address what it describes as inaccurate and misleading media reports about the company and its subsidiaries.